Shijiazhuang Yiling Pharmaceutical (002603) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
29 Apr, 2026Executive summary
Revenue for Q1 2026 reached ¥2.44 billion, up 3.46% year-over-year.
Net profit attributable to shareholders was ¥408.85 million, a 25.43% increase year-over-year.
Operating cash flow surged 79.57% to ¥610.71 million compared to the same quarter last year.
Financial highlights
Basic and diluted EPS were both ¥0.2447, up 25.42% year-over-year.
Gross margin improved as net profit growth outpaced revenue growth.
Net assets attributable to shareholders rose 3.72% from year-end 2025 to ¥11.40 billion.
Total assets increased 3.68% to ¥14.18 billion from year-end 2025.
Outlook and guidance
Management highlighted increased investment in financial products and higher prepayments from customers, indicating confidence in future operations.
Latest events from Shijiazhuang Yiling Pharmaceutical
- Net profit rose 277.56% to ¥1.29 billion on 20.24% revenue growth, with robust cash flow.002603
Q4 202528 Apr 2026 - 2024 net loss driven by sales drop, inventory write-downs, and high R&D; cost control prioritized.002603Q4 202422 Dec 2025
- Net profit soared 80.33% to ¥1.00 billion despite a 7.82% revenue decline.002603Q3 202528 Oct 2025
- Net profit rose 26% to ¥669 million despite a 12% revenue drop, with strong cash flow.002603Q2 202528 Aug 2025
- Revenue and profit declined sharply year-over-year, but operating cash flow improved.002603Q3 202413 Jun 2025
- Revenue and profit declined sharply, but R&D and market leadership in core products remain strong.002603Q2 202413 Jun 2025
- Net profit grew 7.25% year-over-year in Q1 2025 despite a 6.52% revenue drop.002603Q1 20256 Jun 2025